Amylyx Pharmaceuticals
This role serves as a strategic partner within Market Access, leading pricing strategy, analytics, gross-to-net modeling, and contracting evaluation to support the launch of avexitide for post-bariatric hypoglycemia. The position involves building financial models, analyzing payer and PBM trends, and generating actionable insights to inform access and reimbursement decisions. It requires collaboration with cross-functional teams to ensure compliant decision-making and effective market access strategies.
Headquarters
Cambridge, Massachusetts, United States
Company Size
201-500 employees
Amylyx Pharmaceuticals is a biopharmaceutical company focused on developing novel therapies for diseases with high unmet needs, including Post-Bariatric Hypoglycemia (PBH), Wolfram Syndrome, and Amyotrophic Lateral Sclerosis (ALS). Its lead program, Avexitide, is being evaluated in the pivotal Phase 3 LUCIDITY clinical trial for PBH. Amylyx advances its pipeline using rigorous science, well-defined mechanistic rationale, and a strong commitment to the patient communities it serves.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Amylyx Pharmaceuticals.
5% below the average for this role
Wall Street Zen Upgrades Amylyx Pharmaceuticals (NASDAQ:AMLX) Stock Rating
4 days ago
Senior Director, Market Access Pricing & Contracting
NewAmsterdam Pharma
VP Market Access & Pricing
MoonLake Immunotherapeutics
Senior Director, Market Access, Trade & IDN Analytics
Madrigal Pharmaceuticals
Director, Pricing Strategy and Market Access
Jobgether
Director, Market Access Deal Analytics
Axsome Therapeutics
Contracts & Pricing Strategy, Associate Director
Amgen